









Markets
/
Stocks
/
nasdaq-sttk
/

Shattuck Labs Inc

STTK

2.280USD

+0.050+2.24%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

109.22MMarket Cap

LossP/E TTM



Shattuck Labs Inc

2.280

+0.050+2.24%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

67 / 506

Overall Ranking

159 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

2.307

Target Price

+3.44%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 777.45% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 5.72M.

Undervalued

The company’s latest PE is -1.89, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 35.33M shares, decreasing 15.23% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.15M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 6.26.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.82, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 42.20%.

Score

Industry at a Glance

Previous score

6.82

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.35

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.67

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.03

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.85, which is -54.51% below the recent high of -0.84 and 4.15% above the recent low of -1.77.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 67/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.71, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Shattuck Labs Inc is 2.00, with a high of 4.00 and a low of 0.92.

Score

Industry at a Glance

Previous score

7.71

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

2.307

Target Price

+3.44%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Shattuck Labs Inc

STTK

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.44, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 2.72 and the support level at 1.27, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.44

Change

-0.04

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(0)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MACD(12,26,9)

0.117

Buy

RSI(14)

70.713

Buy

STOCH(KDJ)(9,3,3)

90.906

Overbought

ATR(14)

0.275

High Vlolatility

CCI(14)

118.450

Buy

Williams %R

2.985

Overbought

TRIX(12,20)

4.004

Buy

StochRSI(14)

74.566

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

2.076

Buy

MA10

1.992

Buy

MA20

1.561

Buy

MA50

1.124

Buy

MA100

1.055

Buy

MA200

1.103

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 73.76%, representing a quarter-over-quarter decrease of 2.25%. The largest institutional shareholder is The Vanguard, holding a total of 2.15M shares, representing 4.48% of shares outstanding, with 11.11% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Prosight Capital

6.64M

Redmile Group, LLC

5.54M

Adage Capital Management, L.P.

4.67M

Hornblower Capital Holdings, LLC

2.89M

Houghton Capital Holdings, LLC

2.61M

The Vanguard Group, Inc.

Star Investors

2.40M

-0.33%

The Clark Estates Inc.

1.48M

Pinnacle Associates Ltd.

1.30M

-1.89%

683 Capital Management LLC

1.05M

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.15, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.73. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.